Video

Dr. Weber on Adjuvant Approaches in Stage III Melanoma

Jeffrey S. Weber, MD, PhD, discusses adjuvant approaches in stage III melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses adjuvant approaches in stage III melanoma.

Dabrafenib (Tafinlar) and trametinib (Mekinist) was the first BRAF/MEK combination that was approved for patients with metastatic melanoma. The combination showed a significantly prolonged survival compared with single-agent dabrafenib or vemurafenib (Zelboraf). Subsequently, the combination of vemurafenib and cobimetinib (Cotellic) was approved in the metastatic setting. The combination of encorafenib (Braftovi)and binimetinib (Mektovi) is also approved in the metastatic setting. The phase III COMBI-AD trial was the first trial that evaluated these drugs in the adjuvant setting.

The double-blind, placebo-controlled trial enrolled 870 patients with resected, stage III melanoma who harbored BRAF V600E or V600K mutations. Patients were randomized to the combination of dabrafenib and trametinib or two matched placebo tablets. The estimated 3-year rate of relapse-free survival was 58% in the combination arm versus 39% in the placebo arm (HR, 0.47; 95% CI, 0.39-0.58; P <.001). The 3-year overall survival rate was 86% in the combination arm versus 77% in the placebo arm (HR, 0.57; 95% CI,0.42-0.79; P =.0006).

The most common reason for treatment discontinuation was the occurrence of adverse events and disease recurrence in the combination and placebo arms, respectively. Regardless, dabrafenib and trametinib is a beneficial treatment for patients with resected, stage III melanoma, concludes Weber.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity